Skip to content
DataLookout
Menu

NCT05241392

Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma

StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 3 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 20 words Show 4 more changesShow less
    • Interventions modified
    • Secondary endpoints: details revised at 1 of 5 entries
    • Publications: details revised at 2 of 2 entries
    • Collaborators expanded, about 5 words
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Dec 31, 2024 to Nov 30, 2024
    • Study completion date: Dec 31, 2024 to Dec 31, 2026
    • Site details revised
    v4
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of Dose Limiting Toxicity (DLT)
Timeframe: three months post CAR-T cells infusion
Safety:Incidence and severity of adverse events
Timeframe: three months post CAR-T cells infusion

Secondary (5)

Efficacy:Overall survival rate at 12 months
Efficacy:objective remission rate
pharmacokinetics:Cmax
pharmacokinetics:Tmax
pharmacokinetics:AUC

Arms and interventions

CAR-T cell therapyExperimental

Dose-escalation phase: A "3+3" dose-escalation design is used to determine MTD \& R2PD. Anti-B7-H3 autologous CAR-T cells were given biweekly to patients at the following doses for each cycle, and 4 cycles as one course. Dose1: 3 patients at a dose of 20 million cells for each cycle. Dose 2: 3 patients at a dose of 60 million cells for each cycle. Dose 3: 3 patients at a dose of 150 million cells for each cycle. Dose 4: 3 patients at a dose of 450 million cells for each cycle. Dose 5: 3 patients at a dose of 900 million cells for each cycle. R2PD confirmation phase: Determine the R2PD based on the results from the previous dose-escalation study; Treat another 12 patients with anti-B7-H3 autologous CAR-T cells biweekly at the R2PD to further confirm the safety of R2PD. At each dose phase, if the patients show tolerate and response to the treatment, these patients would receive several courses of treatment at PI's discretion.

Biologicals: B7-H3-targeting CAR-T cells/TX103-CAR-T Cell Injection

Sites

1 site in 1 country

  • Beijing Tiantan HospitalBeijing, Beijing Municipality, China